華納藥廠(688799.SH):擬超1億元參設鵲山華滋
格隆匯4月19日丨華納藥廠(688799.SH)公佈,為跟上世界範圍內大分子創新藥日益成為主流用藥的潮流與大趨勢,藉助專業投資機構的投資經驗和資源,探索公司所在醫藥行業相關創新應用領域的投資機會,加強公司在大分子藥物研發領域的能力,積極利用外部人才、資本,高效、低風險完成公司新藥研發轉型、產品升級的戰略,公司本次擬作為有限合夥人與北京鵲山投資管理有限公司、湖南金陽投資集團有限公司及其他合夥人簽署《合夥協議》,共同出資發起設立私募基金湖南鵲山華滋產業投資合夥企業(有限合夥)。
鵲山華滋將重點關注我國具備較高發病率且臨牀尚有大量未解決難題的病種領域,以及其中的大分子創新藥、器械領域的投資、以參股投資的方式對屬於該等領域內的未上市企業進行創業投資,或者在做深入調查研究後發起研發型項目公司。公司擬以自有資金認繳出資不超過人民幣10,000.00萬元,出資比例佔基金總認繳出資額的39.60%,具體情況以最終簽署的《合夥協議》為準。
基金的投資方向聚焦於中國境內的醫療大健康領域,通過對醫療大健康領域內的未上市企業進行創業投資或者發起設立項目研發公司等方式進行投資,與公司主營業務具備相關性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.